DexCom, Inc. (NASDAQ:DXCM) – Equities researchers at Leerink Swann increased their FY2018 earnings per share (EPS) estimates for shares of DexCom in a report released on Tuesday, December 4th. Leerink Swann analyst D. Antalffy now expects that the medical device company will post earnings per share of ($0.14) for the year, up from their prior forecast of ($0.16). Leerink Swann also issued estimates for DexCom’s Q2 2019 earnings at $0.05 EPS, Q3 2019 earnings at $0.06 EPS, FY2019 earnings at $0.33 EPS, FY2020 earnings at $1.10 EPS, FY2021 earnings at $1.91 EPS and FY2022 earnings at $2.95 EPS.
DexCom (NASDAQ:DXCM) last posted its earnings results on Tuesday, November 6th. The medical device company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.29. DexCom had a net margin of 4.72% and a negative return on equity of 2.89%. The firm had revenue of $266.70 million during the quarter, compared to analyst estimates of $242.72 million. The firm’s revenue was up 44.5% compared to the same quarter last year.
DexCom stock opened at $129.47 on Friday. The company has a current ratio of 4.71, a quick ratio of 4.43 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $11.36 billion, a price-to-earnings ratio of -223.22 and a beta of 0.55. DexCom has a twelve month low of $51.04 and a twelve month high of $152.14.
In other news, EVP Andrew K. Balo sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 14th. The shares were sold at an average price of $143.13, for a total value of $715,650.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Richard Doubleday sold 1,736 shares of the business’s stock in a transaction dated Friday, November 23rd. The stock was sold at an average price of $121.35, for a total transaction of $210,663.60. Following the completion of the sale, the executive vice president now directly owns 66,804 shares of the company’s stock, valued at approximately $8,106,665.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 149,745 shares of company stock valued at $21,210,998. 1.80% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in DXCM. JS Capital Management LLC acquired a new position in DexCom in the 3rd quarter valued at approximately $100,000. Stratos Wealth Partners LTD. acquired a new stake in shares of DexCom during the 3rd quarter worth about $124,000. IBM Retirement Fund acquired a new stake in shares of DexCom during the 3rd quarter worth about $203,000. HPM Partners LLC acquired a new stake in DexCom in the 3rd quarter valued at about $203,000. Finally, Brighton Jones LLC bought a new position in shares of DexCom in the 3rd quarter valued at about $204,000. 99.05% of the stock is owned by institutional investors and hedge funds.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: Price to Earnings Ratio (PE), For Valuing Stocks
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.